IOVA — Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Total product revenue increased by 13% quarter-over-quarter to approximately $68 million, driven primarily by Amtagvi sales of about $58 million and Proleukin revenue of nearly $10 million.
• Gross Margin: Improved to approximately 43%, up from previous quarters, attributed to cost optimization and a reduction in cost of sales by approximately 21%.
• Expense Management: Total costs and expenses decreased by approximately 10% over the prior quarter, excluding restructuring charges of about $5 million.
• Cash Position: As of September 30, 2025, cash reserves were approximately $307 million, expected to fund operations into Q2 2027.
• Revenue Guidance: The company reiterated its full-year 2025 revenue guidance of $250 million to $300 million.

2. Strategic Updates and Business Highlights

• Pipeline Progress: Iovance is focused on accelerating the adoption of Amtagvi across academic and community authorized treatment centers (ATCs). Initial treatments in community settings are underway, with a focus on earlier patient referrals.
• Clinical Trials: Positive interim data from the LUN-202 trial for Lifileucel in non-squamous non-small cell lung cancer showed a 26% objective response rate and unprecedented durability. Enrollment is expected to complete in 2026.
• Manufacturing Strategy: The company announced the centralization of manufacturing at its internal facility, the Iovance Cell Therapy Center (iCTC), expected to enhance capacity and reduce costs starting in early 2026.
• Market Expansion: Iovance is expanding into international markets, with approvals anticipated in Canada, the UK, Australia, and Switzerland, with a long-term view towards revenue generation from these markets.

3. Forward Guidance and Outlook

• The company anticipates a strong fourth quarter driven by new ATCs and increasing Proleukin sales.
• Iovance expects to achieve peak sales for Amtagvi exceeding $1 billion in the U.S. and sees significant potential in international markets and additional indications, particularly in lung cancer.
• The company is on track for a supplemental biologics license application for Lifileucel in non-small cell lung cancer, with a potential launch in the second half of 2027.

4. Challenges and Points of Concern

• Regulatory Risks: While the company is confident in its engagement with the FDA regarding the LUN-202 trial, regulatory approval processes remain inherently uncertain.
• Market Competition: The competitive landscape for lung cancer therapies is robust, and Iovance must demonstrate the superiority of its TIL therapy over existing treatments.
• Expense Management: Continued focus on cost control is necessary to maintain profitability, especially as the company transitions to in-house manufacturing.
• Global Expansion Risks: There is uncertainty regarding the timeline and revenue generation from international markets, which may not contribute significantly until 2027.

5. Notable Q&A Insights

• Lung Cancer Data: Analysts inquired about the durability of the efficacy signal in the LUN-202 trial, with management expressing confidence in maintaining or improving efficacy as enrollment continues.
• Community ATC Activation: Questions about the timeline for community ATCs to treat patients indicated that initial treatments are starting, with expectations for ramp-up over the next few quarters.
• Gross Margin Improvement: Management clarified that improvements in gross margin are driven by reduced patient drop-off and manufacturing success rates, alongside cost reduction measures.
• Global Strategy: Iovance emphasized a cautious approach to partnerships for global expansion, focusing on internal capabilities while acknowledging that significant revenue from these markets is not expected until 2027.

Overall, Iovance Biotherapeutics is making steady progress in its commercial and clinical initiatives, with a strong focus on revenue growth and operational efficiency, while navigating the challenges of regulatory approval and competitive pressures in the oncology market.